ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials
Rheumatol 2024 2024;00:1–11 DOI 10.1093/rheumatology/keae269
Arnold et al. assessed musculoskeletal (MSK) inflammation in ANA-associated rheumatic diseases (RMDs) and redefined ANA-associated arthritis into two distinct multi-disease clusters based on disease activity, which may support a more targeted approach to treatment. The authors confirmed that MSK inflammation is a key feature across diagnoses and responded similarly to treatments.
The study's key focus was to evaluate the clinical and immunological characteristics of ANA-associated arthritis in a multi-disease cohort and to propose new basket groupings for future trials. This observational study utilised patient-reported outcomes and immunological markers for reclassification.